| Open Document File Size: 118,90 KBShare Result on Facebook
City Beltsville / MACMIS / San Diego / / Company Ligand Pharmaceuticals Inc. / CASE / See Mr. Blissenbach Ligand Pharmaceuticals Inc. / Alteon Inc. / / Event FDA Phase / / Facility Laboratory Tests / / / IndustryTerm treatment of cutaneous manifestations of cutaneous Tcell lymphoma / treatment of cutaneous T-cell lymphoma / / MedicalCondition allergic reaction / chest pain / headache / lymphoma experienced hypoalbuminemia / leukopenia / recurrent cutaneous T-cell lymphoma / liver failure / infectious complications / cutaneous Tcell lymphoma / Vascular Leak Syndrome / nausea/vomiting / nausea / thrombocytopenia / anaphylaxis / syncope / laryngismus / cutaneous infection / Acute hypersensitivity / tachycardia / hyperlipemia / diarrhea / non-CTCL cancers / pruritus / mycosis fungoides / back pain / birth defects / hypoalbuminemia / hypotension / tumor / cutaneous T-cell lymphoma / reversible leukopenia / advanced non-CTCL cancer / cancer / chills/fever / tumors / hypothyroidism / dyspnea / clinical hypothyroidism / dysphagia / This syndrome / hypertriglyceridemia / chills / cardiovascular disease / fever / seizure / pain / vomiting / Pancreatitis / infection / hypercholesteremia / Acute pancreatitis / rash / cholestasis / anemia / syndrome / / MedicalTreatment antineoplastic therapy / chemotherapy / radiotherapy / counseling / cardiopulmonary resuscitation / / Organization Food and Drug Administration / Division of Drug Marketing / Advertising / and Communications / DEPARTMENT OF HEALTH / / Person Thomas Abrams / / Position physician / PRECAUTIONS General / Director / FACSIMILE Henry Blissenbach President and Chief Executive Officer / / Product gemfibrozil / Pentostatin / Targretin / ONTAK / IL-2R / CD25 / MACMIS / ONTAK® (denileukin diftitox) / / ProvinceOrState Maryland / California / / Technology chemotherapy / /
SocialTag |
Ontak and Targretin Warning Letter